Nektar Therapeutics - Common Stock — Cash Flow (NASDAQ:NKTR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -313.29 M-412.66 M-304.01 M-192.61 M-175.71 M-208.51 M -233.79 M Cash from investing activities 496.21 M202.78 M365.83 M139.56 M142.57 M-1.2 M -844.4 M Cash from financing activities -80.35 M36.24 M1.51 M30 K42.12 M180.57 M 1.07 B Free cash flow -313.29 M-412.66 M-304.01 M-192.61 M-175.71 M-208.68 M -234.03 M

News

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Retail Sales Weaken in July

U.S. Stock Futures Mixed, Heads for a Winning Week

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR)

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR)

Wall Street Lunch: BP Slips After Ousting Chairman Albert Manifold Over Governance Concern

5 Healthcare Stocks Set to Join the Russell 3000 - TipRanks.com